Maghemite Nanoparticle Phosphate Adsorbent Coating
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current phosphate binders for patients with impaired renal function, such as those based on calcium, aluminium, and lanthanum, have adverse effects and are costly, while iron-based binders face challenges with iron toxicity and systemic overload, limiting their effectiveness and safety for long-term use.
Innovation Solution
Development of a phosphate adsorbent using inverse spinel iron oxide nanoparticles with a monosaccharide or disaccharide coating, specifically maghemite or magnetite, to enhance phosphate binding capacity and reduce adverse effects, ensuring stability and safety for prolonged use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If calcium-based phosphate binders are used, then cost is reduced, but adverse effects increase (calcium serum levels increase, vascular calcification accelerates)
Solution Approach 1:
The patent changes the chemical composition parameter from calcium-based to iron oxide-based phosphate binders. This parameter change maintains cost-effectiveness while reducing adverse effects such as vascular calcification and hypercalcemia, as iron oxide binders do not cause calcium overload despite effective phosphate binding
Solution Approach 2:
The patent uses composite iron oxide materials with specific crystalline structures (maghemite, magnetite, goethite) and controlled particle sizes (nanoparticles to micro particles). These composite structures provide effective phosphate binding capacity while maintaining safety profile, combining the benefits of low cost with reduced toxicity compared to traditional calcium or lanthanum-based binders
2Productivity
If aluminium hydroxide is used, then phosphate binding effectiveness is improved, but adverse effects increase (encephalopathy, bone demineralization)
Solution Approach 1:
The patent changes the active ingredient from aluminium hydroxide to iron oxide nanoparticles. This parameter change maintains high phosphate binding effectiveness while eliminating the neurotoxic and bone-destructive effects associated with aluminium absorption, as iron oxide binders do not cross the blood-brain barrier or cause bone demineralization
3Productivity
If lanthanum carbonate is used, then phosphate binding effectiveness is improved, but adverse effects increase (gastrointestinal obstipation, nephrogenic systemic fibrosis)
Solution Approach 1:
The patent changes the chemical composition from lanthanum carbonate to iron oxide-based binders. This parameter change maintains effective phosphate binding while avoiding gastrointestinal obstipation and nephrogenic system fibrosis, as iron oxide binders do not cause lanthanum ion absorption or trigger connective tissue inflammation
Solution Approach 2:
The patent employs iron oxide nanoparticles as a safe, cost-effective alternative to expensive and toxic lanthanum-based binders. The iron oxide nanoparticles provide effective phosphate binding without the severe adverse effects, offering a sustainable treatment option that can be used long-term without causing cumulative toxicity
4Ease of manufacture
If iron-based phosphate binders are used, then cost is reduced and adverse effects are minimized, but iron toxicity and systemic overload occur
Solution Approach 1:
The patent changes the particle size parameter to nanoparticles (1-100 nm) and controls the crystalline structure (maghemite, magnetite, goethite). This parameter change enables effective phosphate binding while minimizing iron release and toxicity, as the controlled nanoparticle structure prevents excessive iron dissolution compared to conventional iron supplements
Solution Approach 2:
The patent applies local quality by coating the iron oxide nanoparticles with specific substances (citrate, tartrate, glucuronic acid, or glutamic acid) that provide stabilization and control iron release. This coating creates a localized protective layer that prevents systemic iron overload while maintaining phosphate binding effectiveness in the gastrointestinal tract
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The phosphate adsorbent effectively binds phosphate in the gastrointestinal tract, reducing serum phosphate levels without significant adverse effects and minimizing iron release, making it a safer and more cost-effective option for long-term treatment of hyperphosphatemia.
Implementation Method 1
The pathomechanism of hyperphosphatemia in patients with reduced renal function is a complex dysregulation of glomerular filtration, tubular reabsorption, and release from bone caused by a hormonal imbalance. In conjunction with calcium imbalance,hyperphosphatemia increases the risk of cardiovascular disease in patients with impaired renal function.
Implementation Method 2
a coating selected from monomeric carbohydrates, in particular monosaccharides or disaccharides, alditols, or mixtures thereof
Data Source
AI summary
The present invention relates to a phosphate adsorbent on the basis of maghemite or maghemite/magnetite comprising (i) an iron oxide core comprising a crystal structure of inverse spinel iron oxide, (ii) a coating selected from monomeric carbohydrates, in particular monosaccharides or disaccharides, alditols, or mixtures thereof, and/or (iii) a pharmaceutical excipient selected from polymeric carbohydrates, wherein the phosphate adsorbent has the form of nanoparticles with a particle size of the iron oxide core (i) of less than 20 nm. The present invention further relates to a method for the production of a phosphate adsorbent on the basis of maghemite or maghemite/magnetite, to pharmaceutical compositions comprising the phosphate adsorbent, and to medical uses thereof, especially for the prevention and/or treatment of hyperphosphatemia.